Yıl: 2021 Cilt: 22 Sayı: 2 Sayfa Aralığı: 127 - 131 Metin Dili: İngilizce DOI: 10.4274/jtgga.galenos.2020.2020.0051 İndeks Tarihi: 19-01-2022

Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy

Öz:
Objective: The aim of this study was to assess the diagnostic values of new biochemical markers that may be an alternative to the oral glucose tolerance test (OGTT) and determine the differences in these markers among three groups of women with varying degrees of glucose homeostasis dysregulation. Material and Methods: This was a prospective study. All women were screened with 50 gram (g) oral glucose and a 100 g OGTT for gestational diabetes mellitus (GDM). The patients were divided into three groups depending on the result of the tests: no evidence of glucose metabolism abnormality (controls); impaired glucose tolerance (IGT); and GDM. All three groups were evaluated for serum human advanced glycation endproducts (AGEs) concentrations, carboxymethyl lysine (CML) concentration and receptor for advanced glycation end-product concentrations (RAGE/AGER), body mass index (BMI), age, fasting glucose levels, obstetrical parameters and gestational age. Results: The study included 180 women divided into 59 (32.8%) GDM, 50 (27.8%) IGT and 71 (39.4%) controls. Age was similar among the three groups. Whereas fasting glucose levels and BMI in the three groups was significantly different, AGEs, CML, RAGE/AGER levels were found as significantly different between the groups (p<0.001). Conclusion: In this study the use of AGEs, CML, and RAGE/AGER concentrations for the diagnosis and screening of gestational diabetes was investigated. It was found that advanced glycation products were significantly elevated in pregnancies with both IGT and GDM. These biochemical markers of glucose homeostasis dysregulation may have potential for GDM screening in the future. (J Turk Ger Gynecol Assoc 2021; 22: 127-31)
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Yalçin HR, Zorlu CG. Threshold value of glucose screening tests in pregnancy: could it be standardized for every population? Am J Perinatol 1996; 13: 317-20.
  • 2. Gregory KD, Kjos SL, Peters RK. Cost of non-insulin-dependent diabetes in women with a history of gestational diabetes: implications for prevention. Obstet Gynecol 1993; 81: 782-6.
  • 3. Khandelwal M, Homko C, Reece EA. Gestational diabetes mellitus: controversies and current opinions. Curr Opin Obstet Gynecol 1999; 11: 157-65.
  • 4. Deerachanawong C, Putiyanun C, Wongswyat M, Serirat S, Jinayon P. Comparison of National Diabetes Data Group and World Health Organization criteria for detecting gestational diabetes mellitus. Diabetologia 1996; 39: 1070-3.
  • 5. American College of Obstetricians and Gynecologists: Diabetes and pregnancy. ACOG Technical Bulletin. Washington, DC 1994.
  • 6. Singh VP, Bali A, Singh N, Singh Jaggi A. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014; 18: 1-14.
  • 7. American Diabetes Association. Gestational Diabetes Mellitus. Diabetes Care 2003; 26: 103-5.
  • 8. Carpenter MW, Couston DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982; 144: 768-73.
  • 9. Coustan DR. Diagnosis of gestational diabetes: What are our objectives? Diabetes 1991;40(Suppl 2): 14-7.
  • 10. Dornhorst A, Rossi M. Risk and prevention of type 2 diabetes in women with gestational diabetes. Diabetes Care 1998; 21(Suppl 2): B43-9.
  • 11. From the American Diabetes Association, Alexandria, Virginia. Originally approved 1997. Modified in 1999 based on the Proceedings of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 1998 ;21: 1-167.
  • 12. Metzger BE, Couston DR. Proceedings of the Fourth İnternational Workshop- Conference on Gestational Diabetes Mellitus. Diabetes Care 1998; 21: 167.
  • 13. Solomon CG, Willett WC, Carey VJ, Rich-Edwards J, Hunter DJ, Colditz GA, et al. A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA 1997; 278: 1078-83.
  • 14. Pallardo LF, Herranz L, Martin-Vaquero P, Garcia-Ingelmo T, Grande C, Jañez M. mpaired fasting glucose and impaired glucose tolerance in women with prior gestational diabetes are associated with a different cardiovascular profile. Diabetes Care 2003; 26: 2318-22.
  • 15. Gaudier FL, Hauth JC, Poist M, Corbett D, Cliver SP. Recurrence of gestational diabetes mellitus. Obstet Gynecol 1992; 80: 755-8.
  • 16. Dudhbhai M, Lim L, Bombard A, Juliard K, Meenakshi B, Trachelenberg Y, et al. Characteristics of patients with abnormal glucose challenge test and normal oral glucose tolerance test results: comparison with normal and gestational diabetic patients. Am J Obstet Gynecol 2006; 194: e42-5.
  • 17. Perruchini D, Fischer U, Spinas GA, Huch R, Huch A, Lehmann R. Using fasting plasma glucose concentrafions to screen for gestational diabetes mellitus. BMJ 1999; 319: 812-5.
  • 18. Thomally PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 1998; 44: 1013-23.
  • 19. Thomalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, BabaeiJadidi R, et al. Quantitative screening of advanced glycation endproducts in cellular and extrasellular proteins by tandem mass spectrometry. Biochem J 2003; 375: 581-92.
  • 20. Vlasaara H. The AGE receptor in the pathogenesis of diabetic complications. Diabetes Meteb Res Rev 2001; 17: 436-43.
  • 21. Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC, Litchfield JE, Ahmed MU, Reddy S, et al. New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant 1996; 11(Suppl 5): 41- 7.
  • 22. Njoroge FG, Monier WM. The chemistry of the Maillard reaction under physiological conditions: a review. Prog Clin Biol Res 1989; 304: 85-107.
  • 23. Zhang Q, Ames JM, Smith RD, Baynes JW, Metz TO. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res 2009; 8: 754-69.
  • 24. Schiekofer S, Andrassy M, Chen J, Rudofsky G, Schneider J, Wendt T, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 2003; 52: 621-33.
  • 25. Sakai M, Oimomi M, Kasuga M. Experimental studies on the role of fructose in the development of diabetic complications. Kobe J Med Sci 2002; 48: 125-36.
  • 26. Li S, Yang H. Relationship between advanced glycation end products and gestational diabetes mellitus. J Matern Fetal Neonatal Med 2019; 32: 2783-9.
  • 27. Bartakova V, Kollarova R, Kuricova K, Sebekova K, Belobradkova J, Kankova K. Serum carboxymethyl-lysine, a dominant advanced glycation end product, is increased in women with gestational diabetes mellitus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160: 70-5.
  • 28. Lobo JP Júnior, Brescansin CP, Santos-Weiss ICR, Welter M, Souza EM, Rego FGM, et al. Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients. Arch Endocrinol Metab 2017; 61: 233-7.
  • 29. Cosson E, Gary F, Nguyen MT, Bianchi L, Sandre-Banon D, Biri L, et al. Gradual increase in advanced glycation end-products from no diabetes to early and regular gestational diabetes: A case-control study. Diabetes Metab 2019; 45: 586-9.
APA Şimşek Tanın Ö, Kara M, Engin-Ustun Y, GÖÇMEN A, Yalvaç E (2021). Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy. , 127 - 131. 10.4274/jtgga.galenos.2020.2020.0051
Chicago Şimşek Tanın Özlem,Kara Mustafa,Engin-Ustun Yaprak,GÖÇMEN Ayşe Yeşim,Yalvaç Ethem Serdar Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy. (2021): 127 - 131. 10.4274/jtgga.galenos.2020.2020.0051
MLA Şimşek Tanın Özlem,Kara Mustafa,Engin-Ustun Yaprak,GÖÇMEN Ayşe Yeşim,Yalvaç Ethem Serdar Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy. , 2021, ss.127 - 131. 10.4274/jtgga.galenos.2020.2020.0051
AMA Şimşek Tanın Ö,Kara M,Engin-Ustun Y,GÖÇMEN A,Yalvaç E Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy. . 2021; 127 - 131. 10.4274/jtgga.galenos.2020.2020.0051
Vancouver Şimşek Tanın Ö,Kara M,Engin-Ustun Y,GÖÇMEN A,Yalvaç E Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy. . 2021; 127 - 131. 10.4274/jtgga.galenos.2020.2020.0051
IEEE Şimşek Tanın Ö,Kara M,Engin-Ustun Y,GÖÇMEN A,Yalvaç E "Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy." , ss.127 - 131, 2021. 10.4274/jtgga.galenos.2020.2020.0051
ISNAD Şimşek Tanın, Özlem vd. "Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy". (2021), 127-131. https://doi.org/10.4274/jtgga.galenos.2020.2020.0051
APA Şimşek Tanın Ö, Kara M, Engin-Ustun Y, GÖÇMEN A, Yalvaç E (2021). Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy. Journal of the Turkish-German Gynecological Association, 22(2), 127 - 131. 10.4274/jtgga.galenos.2020.2020.0051
Chicago Şimşek Tanın Özlem,Kara Mustafa,Engin-Ustun Yaprak,GÖÇMEN Ayşe Yeşim,Yalvaç Ethem Serdar Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy. Journal of the Turkish-German Gynecological Association 22, no.2 (2021): 127 - 131. 10.4274/jtgga.galenos.2020.2020.0051
MLA Şimşek Tanın Özlem,Kara Mustafa,Engin-Ustun Yaprak,GÖÇMEN Ayşe Yeşim,Yalvaç Ethem Serdar Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy. Journal of the Turkish-German Gynecological Association, vol.22, no.2, 2021, ss.127 - 131. 10.4274/jtgga.galenos.2020.2020.0051
AMA Şimşek Tanın Ö,Kara M,Engin-Ustun Y,GÖÇMEN A,Yalvaç E Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy. Journal of the Turkish-German Gynecological Association. 2021; 22(2): 127 - 131. 10.4274/jtgga.galenos.2020.2020.0051
Vancouver Şimşek Tanın Ö,Kara M,Engin-Ustun Y,GÖÇMEN A,Yalvaç E Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy. Journal of the Turkish-German Gynecological Association. 2021; 22(2): 127 - 131. 10.4274/jtgga.galenos.2020.2020.0051
IEEE Şimşek Tanın Ö,Kara M,Engin-Ustun Y,GÖÇMEN A,Yalvaç E "Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy." Journal of the Turkish-German Gynecological Association, 22, ss.127 - 131, 2021. 10.4274/jtgga.galenos.2020.2020.0051
ISNAD Şimşek Tanın, Özlem vd. "Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancy". Journal of the Turkish-German Gynecological Association 22/2 (2021), 127-131. https://doi.org/10.4274/jtgga.galenos.2020.2020.0051